Absence of global hypomethylation in promoter hypermethylated Mixed Lineage Leukaemia-rearranged infant acute lymphoblastic leukaemia

详细信息    查看全文

• 作者：Dominique J.P.M. Stumpel ; Pauline Schneider ; Eddy H.J. van Roon ; Rob Pieters ; Ronald W. Stam ; ^{r.stam@erasmusmc.nl}
• 关键词：Acute lymphoblastic leukaemia ; MLL ; Infant ; Retrotransposon ; DNA methylation
• 刊名：European Journal of Cancer
• 出版年：2013
• 出版时间：January, 2013
• 年：2013
• 卷：49
• 期：1
• 页码：175-184
• 全文大小：1146 K

文摘

Background

Mixed Lineage Leukaemia (MLL)-rearranged acute lymphoblastic leukaemia (ALL) in infants represents a highly aggressive type of leukaemia that is often characterised by severe promoter CpG island hypermethylation. Consequently, MLL-rearranged ALL cells respond well to demethylating cytosine analogue drugs. In human cancer cells, enhanced promoter methylation is typically accompanied by global loss of methylation in non-promoter regions of the genome. In turn, global hypomethylation usually leads to genomic instability, which may have contributed to cancer development.

Design and methods

Here we examined global methylation densities in MLL-rearranged infant ALL (n = 45) samples in comparison with germline MLL infant ALL (n = 11), non-infant B-cell precursor ALL (n = 11) and normal paediatric bone marrow (n = 9) samples. For this we performed high-resolution bisulfite pyrosequencing to determine methylation levels at the repetitive elements LINE-1, Alu and satellite ¦Á (SAT-¦Á). As an additional measure of global methylation levels we used the LUminometric Methylation Assay (LUMA).

Results

We found that MLL-rearranged infant ALL is not characterised by global hypomethylation, despite its characteristic promoter CpG hypermethylation patterns. Instead we observed a moderate trend towards global hypermethylation and demonstrated that these methylated non-promoter sequences are responsive to demethylating agents.

Conclusions

MLL-rearranged infant ALL cells are characterised by an overall methylated genomic state, and both promoter and non-promoter methylation responds to demethylating agents, which may further explain the remarkable sensitivity of these cells for the methylation-inhibiting therapeutics.